MESOBLAST Aktie

 

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presentations at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences held in New York....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

It's that time of day to check out which companies are trending…...

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50.0 million (A$76.8 million)1 of unsecured convertible notes. The funding is available at Mesoblast's option, following shareholder approval, to repay or reduce the amount owing to its secured lenders under the existing loan agreements and for general working capital purposes....

Let's see why Bell Potter is tipping this stock as a buy right now. The post Why Mesoblast shares could rocket 60% higher appeared first on The Motley Fool Australia....

These shares are ending the week in the red. But why? The post Why Lynas, Mesoblast, PEXA, and Sayona Mining shares are tumbling today appeared first on The Motley Fool Australia....

Mesoblast (ASX:MSB) had HotCopper users divided on whether or not the company's…...

Financial Results and Operational Update for the Full Year Ended June 30, 2025 Financial Results and Operational Update for the Full Year Ended June 30, 2025...

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2025....

This stock has exploded in the last month The post Heres what $1k invested in Mesoblast shares a month ago is worth now appeared first on The Motley Fool Australia....

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out....

More big returns could be on the way for buyers of this high risk stock according to Bell Potter. The post Why Mesoblast shares can keep storming higher appeared first on The Motley Fool Australia....

These shares are ending the week with a bang. But why? The post Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher appeared first on The Motley Fool Australia....

ASX investors just sent the Mesoblast share price up 38%. But why? The post The Mesoblast share price just rocketed 38%! Here's why appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation....

The ASX biotech share reached a 10-week high of $1.94 today. The post Why is the Mesoblast share price up 11% in June? appeared first on The Motley Fool Australia....

The overall chronic lower back pain market is expected to boost with the expected launch of emerging therapies such as SP-102 (Scilex Holding), Rexlemestrocel-L (Mesoblast Limited), Cebranopadol (TRN-228) (Tris Pharma), and others, increased awareness, and extensive research in the......

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD)....

Good Afternoon and welcome to HotCopper Highlights for Week 20, I'm Jon…...